RT Journal Article
SR Electronic
T1 Estimating the burden of foodborne gastroenteritis due to nontyphoidal <em>Salmonella enterica, Shigella</em> and <em>Vibrio parahaemolyticus</em> in China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.14.22272393
DO 10.1101/2022.03.14.22272393
A1 Li, Yan-Jun
A1 Yang, Yun-Fan
A1 Zhou, Yi-Jing
A1 Zhang, Rong-Hua
A1 Liu, Cheng-Wei
A1 Liu, Hong
A1 Li, Xiu-Gui
A1 Chen, Wen
A1 Chen, Yan
A1 Wu, Yong-Ning
YR 2022
UL http://medrxiv.org/content/early/2022/03/16/2022.03.14.22272393.abstract
AB To estimate the incidence of foodborne gastroenteritis caused by nontyphoidal Salmonella enterica, Shigella, and Vibrio parahaemolyticus in China, population surveys and sentinel hospital surveillance were implemented in six provinces from July 2010 to July 2011, and a multiplier calculation model for the burden of disease was constructed. The multiplier for salmonellosis and V. parahaemolyticus gastroenteritis was estimated at 4,137 [95% confidence interval (CI) 2,320–5,663], and for shigellosis at 4,356 (95% CI 2,443–5,963). Annual incidence per 100,000 population was estimated as 245 (95% CI 138–336), 67 (95% CI 38–92), and 806 (95% CI 452–1,103) for foodborne salmonellosis, shigellosis, and V. parahaemolyticus gastroenteritis, respectively, indicating that foodborne infection caused by these three pathogens constitutes an important burden to the Chinese healthcare system. Continuous implementation of active surveillance of foodborne diseases, combined with multiplier models to estimate disease burden, makes it possible for us to better understand food safety status in China.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Natural Science Foundation of China (No. 81673175), CAMS Innovation Fund for Medical Science (CIFMS 2019-I2M-5-024) and the Jiangsu Provincial Preventive Medicine Association (No. Y2018084).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the Committee on Human Experimentation of the National Institute for Nutrition and Food Safety, Chinese Center for Disease Control and PreventionI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors